Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Protara Therapeutics, Inc. (Nasdaq: TARA) has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics, Inc. (Nasdaq: TARA) has announced its participation in the H.C. Wainwright Global Investment Conference from May 23 to May 26, 2022. Their prerecorded presentation will be available on May 24, 2022, at 7:00 a.m. ET. Interested viewers can access it via the Events and Presentations section of Protara's website, where it will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for intestinal failure-related liver disease.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was +1.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright Global Investment Conference being held May 23 through May 26, 2022.
The prerecorded presentation will become available on Tuesday, May 24, 2022 at 7:00 a.m. ET and can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for 90 days following the presentation.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.